Terms: = Colorectal cancer AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK AND Treatment
47 results:
1. Clinical characteristics and treatment patterns of patients with
Willis C; Au T; Hejazi A; Griswold C; Schabath MB; Thompson J; Malhotra J; Federman N; Ko G; Appukkuttan S; Warnock N; Kong SX; Hocum B; Brixner D; Stenehjem D
J Manag Care Spec Pharm; 2024 Jul; 30(7):672-683. PubMed ID: 38950155
[TBL] [Abstract] [Full Text] [Related]
2. Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.
Kato Y; Matsumoto M; Takano N; Hirao M; Matsuda K; Tozuka T; Onda N; Nakamichi S; Takeuchi S; Miyanaga A; Noro R; Gemma A; Seike M
Cancer Med; 2024 Jun; 13(12):e7393. PubMed ID: 38923428
[TBL] [Abstract] [Full Text] [Related]
3. Estimating the Prognostic Value of the Ntrk Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
Santi I; Vellekoop H; M Versteegh M; A Huygens S; Dinjens WNM; Mölken MR
Mol Diagn Ther; 2024 May; 28(3):319-328. PubMed ID: 38616205
[TBL] [Abstract] [Full Text] [Related]
4. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
[TBL] [Abstract] [Full Text] [Related]
5. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
Taşçı EŞ; Oyan B; Sönmez Ö; Mutlu AU; Atcı MM; Sakin A; Öner İ; Çınkır HY; Eryılmaz MK; Çağlayan D; Balçık OY; Paksoy N; Karabulut S; Salim DK; Bilir C; Özen M; Özçelik M; Arıcan A; Akagündüz B; İnal A; Aydın D; Özer L; Gülmez A; Turhal NS; Esen SA; Algın E; Akbaş S; İriağaç Y; Şakalar T; Ünal Ç; Er Ö; Seçmeler Ş; Bozkurt M
BMC Cancer; 2024 Jan; 24(1):16. PubMed ID: 38166764
[TBL] [Abstract] [Full Text] [Related]
6. Ntrk fusions in solid tumours: what every pathologist needs to know.
Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of surgical outcomes of laparoscopic versus open surgery for locally advanced mid-transverse colon cancer.
Iguchi K; Numata M; Shiozawa M; Kazama K; Sawazaki S; Katayama Y; Numata K; Higuchi A; Godai T; Sugano N; Mushiake H; Rino Y
Langenbecks Arch Surg; 2023 Jun; 408(1):222. PubMed ID: 37266706
[TBL] [Abstract] [Full Text] [Related]
8. China special issue on gastrointestinal tumors-Ntrk fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide trk inhibitor treatment.
Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
[TBL] [Abstract] [Full Text] [Related]
9. Analysis Of Common Somatic Mutations In colorectal Carcinoma And Associated Dysregulated Pathwaysarts.
Hassan S; Khatoon A; Bukhari U; Mirza T
J Ayub Med Coll Abbottabad; 2023; 35(1):137-143. PubMed ID: 36849394
[TBL] [Abstract] [Full Text] [Related]
10. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy.
Hua H; He W; Chen N; He Y; Wu G; Ye F; Zhou X; Li Y; Ding Y; Zhong W; Teng L; Jiang W; Sheng Q
Front Immunol; 2022; 13():974793. PubMed ID: 36700211
[TBL] [Abstract] [Full Text] [Related]
11. A reciprocal feedback between colon cancer cells and Schwann cells promotes the proliferation and metastasis of colon cancer.
Han S; Wang D; Huang Y; Zeng Z; Xu P; Xiong H; Ke Z; Zhang Y; Hu Y; Wang F; Wang J; Zhao Y; Zhuo W; Zhao G
J Exp Clin Cancer Res; 2022 Dec; 41(1):348. PubMed ID: 36522730
[TBL] [Abstract] [Full Text] [Related]
12. treatment Patterns of Real-World Patients with trk Fusion cancer Treated by US Community Oncologists.
Klink AJ; Kavati A; Gassama A; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 Sep; 17(5):549-561. PubMed ID: 36089643
[TBL] [Abstract] [Full Text] [Related]
13. Timing of Ntrk Gene Fusion Testing and treatment Modifications Following trk Fusion Status Among US Oncologists Treating trk Fusion cancer.
Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
[TBL] [Abstract] [Full Text] [Related]
14. Ntrk fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability.
Wang H; Li ZW; Ou Q; Wu X; Nagasaka M; Shao Y; Ou SI; Yang Y
Cancer Med; 2022 Jul; 11(13):2541-2549. PubMed ID: 35506567
[TBL] [Abstract] [Full Text] [Related]
15. The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic trk fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma.
Suh K; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2022 Jun; 28(6):622-630. PubMed ID: 35362337
[No Abstract] [Full Text] [Related]
16. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric cancer with Ntrk Overexpression.
Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
[TBL] [Abstract] [Full Text] [Related]
17. Ntrk fusions in colorectal cancer: clinical meaning and future perspective.
Ratti M; Grizzi G; Passalacqua R; Lampis A; Cereatti F; Grassia R; Hahne JC
Expert Opin Ther Targets; 2021 Aug; 25(8):677-683. PubMed ID: 34488530
[TBL] [Abstract] [Full Text] [Related]
18. Patient-reported outcomes from STARtrk-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and Ntrk fusion-positive solid tumours.
Paz-Ares L; Barlesi F; Siena S; Ahn MJ; Drilon A; Conley A; Rolfo C; Wolf J; Seto T; Doebele R; Kapre A; Chen D; McCallum S; Osborne S; Demetri G
ESMO Open; 2021 Jun; 6(3):100113. PubMed ID: 33930659
[TBL] [Abstract] [Full Text] [Related]
19. trkB/C-induced HOXC6 activation enhances the ADAM8-mediated metastasis of chemoresistant colon cancer cells.
Park GB; Choi S; Yoon YS; Kim D
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846772
[TBL] [Abstract] [Full Text] [Related]
20. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (trk) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract] [Full Text] [Related]
[Next]
